PD for Tue 01 Jul 2025
Leadership change at National Pharmacies, TGA to tackle medical device safety issues, new PBS listings live today, and more Click…
FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies
FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.
FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder…
AdaptHealth Corp. Closes Transaction to Dispose of Certain Home Infusion Assets and Reduces Debt
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home…
Pulmonary Hypertension Associated With Increased Risk of Progression in Patients With Myeloproliferative Neoplasms
Pulmonary hypertension significantly increases the risk of disease progression and cardiovascular events in patients with myelofibrosis, emphasizing a need for…
Michigan doctor sentenced in $6.3 million Medicare fraud scheme
A Michigan doctor has been sentenced to four years in prison for a $6.3 million Medicare fraud scheme in which…
Amazon projected to ship more than USPS by 2028: Pitney Bowes
The company’s logistics arm has already surpassed FedEx and UPS in terms of U.S. volume after years of blistering growth.
Ropeginterferon Alfa 2b Is Well-Tolerated, Efficacious in Treatment of Prefibrotic Myelofibrosis
Ropeginterferon alfa-2b shows promising results in treating pre-primary myelofibrosis, enhancing clinical responses and safety in patients.
Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
LITTLE ELM, Texas–(BUSINESS WIRE)–Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends…
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive…